Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 343

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 343
---
 to cash and cash equivalents, bank deposits, trade receivables, and other receivables.

The Company’s cash, cash equivalents and short-term bank deposits at December 31, 2023, and 2024 were deposited with highly rated major Israeli and U. S. banks. In the Company’s opinion, the credit risk associated with these balances is remote.

The Company considers its maximum exposure to credit risk to be as follows:

December 31,
December 31,
2023
2023
───────────────────────────────────────────────────────────────────────────
in USD thousands
Assets:
Cash and cash equivalents 4,255 10,436
Short-term bank deposits 38,739 9,126
Trade receivables 358 2,476
Other receivables 830 1,478
Total 44,182 23,516

  Liquidity risk  

Company management monitors rolling forecasts of the Company’s liquidity reserves on the basis of anticipated cash flows and seeks to maintain the liquidity balances at a level that is sufficient to meet its needs.

Although the Company has succeeded in generating revenues from a number of out-licensing transactions, as well as the commercialization of its lead program, motixafortide, during 2024, it cannot determine with reasonable certainty if and when it will become profitable on a current basis. Management believes that the Company’s current cash and other resources will be sufficient to fund its projected cash requirements through the second half of 2026. However, in the event that the Company does not begin to generate sustainable cash flows from its operating activities in the future, the Company will need to carry out significant cost reductions and/or raise additional funding. See also Note 1c regarding the material uncertainty that may cast significant doubt about the Company’s ability to continue as a going concern.

  Fair value of financial instruments  

The different levels of valuation of financial instruments are defined as follows:

  Level 1      Quoted prices (unadjusted) in active markets for identical assets or liabilities.                                                                                          
  Level 2      Inputs, other than quoted prices included within level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices).  
  Level 3      Inputs for the asset or liability that are not based on observable market data (unobservable inputs).                                                                      

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit